Gliclazide belongs to a class of drugs known as sulfonylureas, which are used to treat type 2 diabetes mellitus. Due to its low water solubility and slow dissolution, however, it may also be poorly absorbed in the small intestine and may also be responsible for pharmacokinetic variability. This review assesses solid dispersion techniques used for the improvement of gliclazide dissolution and bioavailability by considering the selection of carrier, amorphization, the methods of manufacture, the characterization of the products and the in vivo–in vitro relationship. Structured literature search was done on PubMed, Scopus, Web of Science and Google Scholar up to October 2024. After screening and eligibility, 66 references comprising of experimental studies and technical sources were included. The evidence reviewed suggests that the dissolution of gliclazide can be improved to a greater or less extent by conventional and advanced solid dispersion systems. Various hydrophilic polymers (PVP K30, copovidone and Soluplus) and surfactant-based carriers (Poloxamer 188 and Gelucire 50/13) have been studied for increasing wettability and decreasing drug crystallinity. Animal studies, mostly in rodents, show increases in relative oral exposure and decreases in Tmax, with some formulations and comparators showing greater and others less effects. Recrystallization, moisture instabilities, added tablet mass and possible change during compaction are all challenges. Solid dispersions have the potential to enhance the dissolution of gliclazide and the pharmacological activity in animals but have not been proven to be beneficial in humans. Additional studies to characterize formulation stability, manufacturing scale-up and human pharmacokinetic and clinical effects are required to validate for clinical relevance.